Apolipoprotein testing market seen reaching $4.09 billion by 2030

The apolipoprotein testing market is projected to rise from $3.11 billion in 2025 to $4.09 billion by 2030, driven by growing cardiovascular disease cases and wider use of advanced diagnostics. North America held the largest regional share in 2025 as the market expands across clinical testing and personalized risk assessment.

Why it matters: - Apolipoprotein testing is becoming more important as clinicians look for better ways to assess cardiovascular risk and guide lipid treatment. - The market’s growth reflects broader demand for early detection tools as cardiovascular disease rates continue to rise. - The sector also points to expanding use of automated diagnostics, molecular testing and personalized medicine in routine care.

What happened: - The Business Research Company projected the apolipoprotein testing market will reach $4.09 billion by 2030. - The market was valued at $3.11 billion in 2025 and is expected to rise to $3.29 billion in 2026. - The forecast implies a 5.9% CAGR from 2025 to 2026 and a 5.5% CAGR from 2026 to 2030. - The company released its "Apolipoprotein Testing Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035." - A free sample of the report is available here.

The details: - Apolipoprotein testing measures specific apolipoprotein proteins in blood to evaluate cardiovascular risk and lipid metabolism. - The test helps clinicians stratify risk and tailor treatment plans to manage lipid levels and prevent cardiovascular incidents. - Growth in the market has been fueled by more cardiovascular disease cases, broader acceptance of lipid testing protocols, expanding diagnostic laboratory networks, rising preventive healthcare awareness and access to standardized apolipoprotein assays. - The report says future growth will be supported by demand for precise cardiovascular diagnostics, more routine molecular testing, personalized medicine strategies, investment in automated diagnostic tools and a stronger focus on early disease risk assessment. - Key trends highlighted in the report include advanced lipid risk assessment tests, preventive cardiovascular evaluations, integration of genetic and protein testing, expansion of automated immunoassay platforms and personalized cardiac risk profiling. - The full report is available here. - North America held the largest share of the global market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - North America leads because of advanced healthcare infrastructure, widespread diagnostic technology adoption and a strong focus on cardiovascular disease management. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The market outlook is tied closely to the burden of cardiovascular disease, not just to lab technology improvements. - The emphasis on genetic and protein testing suggests apolipoprotein testing is being positioned as part of a broader precision-medicine workflow. - North America’s lead suggests mature reimbursement, infrastructure and provider adoption can still outweigh faster growth in emerging markets. - The report’s extra analytics tools signal a push to package market intelligence for investors, manufacturers and diagnostic providers.

What's next: - More adoption of automated immunoassay platforms is likely as labs look for faster and more standardized workflows. - Demand should grow for preventive cardiovascular evaluations and more precise lipid risk assessment. - The market will likely keep expanding if cardiovascular disease rates remain elevated and personalized medicine continues to spread. - The report also lists contact details for Saumya Sahay at The Business Research Company for more information.